Oncotarget

Research Papers:

Identification of KLK10 as a therapeutic target to reverse trastuzumab resistance in breast cancer

Zhuo Wang, Beihong Ruan, Yi Jin, Yulong Zhang, Jiaqiu Li, Liyuan Zhu, Wenxia Xu, Lifeng Feng, Hongchuan Jin and Xian Wang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:79494-79502. https://doi.org/10.18632/oncotarget.13104

Metrics: PDF 943 views  |   HTML 1311 views  |   ?  


Abstract

Zhuo Wang1,*, Beihong Ruan2,*, Yi Jin2,3, Yulong Zhang2, Jiaqiu Li1, Liyuan Zhu2, Wenxia Xu2, Lifeng Feng2, Hongchuan Jin2, Xian Wang1

1Department of Medical Oncology, Key lab of Biotherapy in Zhejiang, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China

2Laboratory of Cancer Biology, Key lab of Biotherapy in Zhejiang, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China

3Department of Clinical Medicine, Ningbo University, Ningbo, China

*These authors contributed equally to this work

Correspondence to:

Xian Wang, email: wangxzju@163.com

Keywords: trastuzumab resistance, KLK10, breast cancer, HER2

Received: September 06, 2016     Accepted: October 12, 2016     Published: November 04, 2016

ABSTRACT

Trastuzumab, the first antibody widely used in anti-HER2 targeted therapy, dramatically improved the overall outcome of HER2 positive breast cancer patients. However, trastuzumab resistance emerged as a major problem in its clinical application. In order to explore mechanisms underlying trastuzumab resistance, we performed RNA-Seq to analyze the gene expression variation in trastuzumab resistant breast cancer cell line. The sequencing result was then combined with the relevant data in TCGA database to conduct a co-expression analysis. We found a series of differentially expressed genes with potential contributions to trastuzumab resistance. Among them, KLK10 was verified to be a potential therapeutic target for reversing trastuzumab resistance. In summary, this study provides a new clue to screen molecular targets and predictive biomarkers for trastuzumab resistance.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13104